drugset / Trial / NCT00784719
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
RandomizedParallel-groupDouble-blindTreatment
Summary
A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.
Timeline
- Start
- 2008-11
- Primary completion
- 2009-10
- Completion
- 2009-10
Publications
- Liew MS, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol. 2012 Dec;96(12):1498-503. doi: 10.1136/bjophthalmol-2012-301767. Epub 2012 Sep 21.
- Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, Liew SH, Cooper SR, Pickering EH. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012 Jul;119(7):e43-50. doi: 10.1016/j.ophtha.2012.03.017. Epub 2012 May 18.
- Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012 Jul;119(7):1328-35. doi: 10.1016/j.ophtha.2012.01.028. Epub 2012 Apr 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 0.05 % | Topical |
| Subject | Tofacitinib | Small molecule | 0.0003 % | Topical |
| Subject | Tofacitinib | Small molecule | 0.001 % | Topical |
| Subject | Tofacitinib | Small molecule | 0.003 % | Topical |
| Subject | Tofacitinib | Small molecule | 0.005 % | Topical |